Therefore, STON2 may be used as a NACT predictor for ovarian cancer patients to provide better guidance for individual treatment strategies, indicating that neoadjuvant chemotherapy may be more available for EOC patients with STON2 overexpression. The gene discussed is STON2; the disease is ovarian carcinoma.